Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Seladelpar improves liver stiffness in PBC: ASSURE interim analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Primary biliary cholangitis
10.1016/s0140-6736(20)31607-x · 2020 · External reference
The diagnosis and management of patients with primary biliary cholangitis
10.1016/j.jhep.2017.03.022 · 2017 · External reference
Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome
10.1016/j.jhep.2011.02.031 · 2011 · External reference
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study
10.1053/j.gastro.2014.08.029 · 2014 · External reference
Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis
10.1111/apt.70391 · 2026 · External reference
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
10.1097/hep.0000000000000529 · 2024 · External reference
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase
10.14309/ajg.0000000000000557 · 2020 · External reference
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis
10.1016/j.jhep.2022.06.017 · 2022 · External reference
Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis
10.1002/hep.25599 · 2012 · External reference
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis
10.1016/j.cgh.2024.06.035 · 2024 · External reference
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis
10.1016/j.jhep.2025.09.024 · 2026 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
10.1056/nejmoa2312100 · 2024 · External reference
Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway
10.1016/j.jbc.2022.102056 · 2022 · External reference
Selective PPARδ Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators
10.3390/molecules29215189 · 2024 · External reference
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
10.14309/ajg.0000000000003603 · 2025 · External reference
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
2025 · External reference
Unresolved reference
External reference
Baveno VII - Renewing consensus in portal hypertension
10.1016/j.jhep.2021.12.022 · 2022 · External reference
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis
10.1016/j.cgh.2024.07.003 · 2024 · External reference
Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world
2025 · External reference
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis
10.1016/j.cgh.2018.12.028 · 2019 · External reference
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response
10.1111/apt.15533 · 2019 · External reference
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
10.1056/nejmoa1714519 · 2018 · External reference
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis
10.1016/j.cgh.2024.10.020 · 2025 · External reference
EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis
2026 · External reference
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
10.14309/ajg.0000000000003603 · 2025 · External reference
